+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of K562 cells using CCNE1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using CCNE1 mouse mAb with DAB staining.    

  
  

CCNE1 (Cyclin E1) is a key regulatory protein involved in cell cycle progression, primarily governing the transition from the G1 phase to the S phase. It forms a complex with cyclin-dependent kinase 2 (CDK2), facilitating phosphorylation of retinoblastoma (Rb) protein, which releases E2F transcription factors to drive DNA replication. Overexpression of CCNE1 is frequently observed in various cancers, including ovarian, breast, and endometrial cancers, and is associated with genomic instability, tumor aggressiveness, and poor prognosis.

CCNE1 antibodies are critical tools for detecting and quantifying CCNE1 expression in research and diagnostics. These antibodies enable the study of cell cycle dysregulation in cancer, assessment of CCNE1 as a potential biomarker, and evaluation of therapeutic strategies targeting cyclin-CDK complexes. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF).

Recent studies highlight CCNE1 amplification as a resistance mechanism to CDK4/6 inhibitors, driving interest in CCNE1-targeted therapies, such as CDK2 inhibitors or synthetic lethality approaches. However, challenges remain in developing specific inhibitors due to structural similarities among cyclins. Validated CCNE1 antibodies are essential for advancing these investigations, emphasizing the need for high specificity and reproducibility in experimental models and clinical samples.